Technology

Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session

Twist Bioscience Corporation TWST was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $21.06 to $26.12 in the past one-month time frame.

The move came after the company announced that it has implemented Battelle’s ThreatSEQ web service DNA screening platform for advanced biosecurity.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Twist Bioscience currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Twist Bioscience Corporation Price

Twist Bioscience Corporation Price | Twist Bioscience Corporation Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider a better-ranked stock like Advaxis, Inc. ADXS, which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
 
Is TWST going up? Or down? Predict to see what others think:Up or Down

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.

See Latest Stocks Today >>


Click to get this free report

Advaxis, Inc. (ADXS): Free Stock Analysis Report

Twist Bioscience Corporation (TWST): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.